Switch theme
Sign up to access all valuation multiples
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
2010
128
LTM Revenue $84.5M
LTM EBITDA n/a
$137M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
OptiNose has a last 12-month revenue of $84.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, OptiNose achieved revenue of $78.2M and an EBITDA of -$1.2M.
OptiNose expects next 12-month revenue of XXX and NTM EBITDA of XXX
See OptiNose valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $71.0M | $78.2M | XXX | XXX | XXX |
| Gross Profit | $67.0M | $62.4M | XXX | XXX | XXX |
| Gross Margin | 94% | 80% | XXX | XXX | XXX |
| EBITDA | -$15.6M | -$1.2M | XXX | XXX | XXX |
| EBITDA Margin | -22% | -2% | XXX | XXX | XXX |
| Net Profit | -$74.8M | -$35.5M | XXX | XXX | XXX |
| Net Margin | -105% | -45% | XXX | XXX | XXX |
| Net Debt | $34.3M | $56.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, OptiNose's stock price is $9.
OptiNose has current market cap of $92.1M, and EV of $137M.
See OptiNose trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $137M | $92.1M | XXX | XXX | XXX | XXX | $-2.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, OptiNose has market cap of $92.1M and EV of $137M.
OptiNose's trades at 1.6x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate OptiNose's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for OptiNose and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $137M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | -114.0x | XXX | XXX | XXX |
| P/E | -4.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -3.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOptiNose's NTM/LTM revenue growth is 23%
OptiNose's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, OptiNose's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate OptiNose's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for OptiNose and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -2% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -92% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 21% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.6M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 112% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OptiNose acquired XXX companies to date.
Last acquisition by OptiNose was XXXXXXXX, XXXXX XXXXX XXXXXX . OptiNose acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was OptiNose founded? | OptiNose was founded in 2010. |
| Where is OptiNose headquartered? | OptiNose is headquartered in United States of America. |
| How many employees does OptiNose have? | As of today, OptiNose has 128 employees. |
| Who is the CEO of OptiNose? | OptiNose's CEO is Dr. Ramy A. Mahmoud, M.D.. |
| Is OptiNose publicy listed? | Yes, OptiNose is a public company listed on NAS. |
| What is the stock symbol of OptiNose? | OptiNose trades under OPTN ticker. |
| When did OptiNose go public? | OptiNose went public in 2017. |
| Who are competitors of OptiNose? | Similar companies to OptiNose include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of OptiNose? | OptiNose's current market cap is $92.1M |
| What is the current revenue of OptiNose? | OptiNose's last 12-month revenue is $84.5M. |
| What is the current EV/Revenue multiple of OptiNose? | Current revenue multiple of OptiNose is 1.6x. |
| What is the current revenue growth of OptiNose? | OptiNose revenue growth between 2023 and 2024 was 10%. |
| Is OptiNose profitable? | Yes, OptiNose is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
